Neutralizing factors as vaccine adjuvants

• US 20070178065A1
• Filed: 07/25/2006
• Published: 08/02/2007
• Est. Priority Date: 05/03/2002
• Status: Abandoned Application

• Current Assignee: University of Medicine and Dentistry of New Jersey (State of New Jersey)
• Original Assignee: University of Medicine and Dentistry of New Jersey (State of New Jersey)
• Inventors: Monken, Claude, Lattime, Edmund
• Application Number:
  US11/492,293
• Publication Number:
  US 20070178065A1
• Time in Patent Office: Days
• US Class Current: 424/93.200
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector

Abstract

The present invention is a vaccine adjuvant composed of a vaccinia virus vector that encodes a polypeptides capable of neutralizing immune suppressive factors thereby enhancing or stimulating an immune response to a vaccine.

Claims

1. A vaccine adjuvant comprising a vaccinia virus vector encoding at least one polypeptide that neutralizes an immune suppressive factor.

2. A method for enhancing an immune response to a vaccine comprising administering a vaccine in combination with the vaccine adjuvant of claim 1 to a subject so that the cells of the subject express the at least one polypeptide thereby enhancing an immune response to the vaccine in the subject.

4. A kit comprising a formulated vaccine adjuvant of claim 1.

3. The method of claim 3, further comprising administering a second vaccinia virus vector encoding an immune active cytokine.